A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies by Kulkarni, Jayashri et al.
  
 
 
 
Kulkarni, Jayashri, Worsley, Roisin, Gilbert, Heather, Gavrilidis, Emorfia, Van Rheenen, Tmsyn E., Wang, Wei, 
McCauley, Kay and Fitzgerald, Paul 2014, A prospective cohort study of antipsychotic medications in 
pregnancy: the first 147 pregnancies and 100 one year old babies, PLoS one, vol. 9, no. 5, Article number : 
e94788, pp. 1-6. 
 
DOI: 10.1371/journal.pone.0094788 
 
 
 
This is the published version. 
 
©2014, The Authors 
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30085069 
 
 
 
 
 
A Prospective Cohort Study of Antipsychotic Medications
in Pregnancy: The First 147 Pregnancies and 100 One
Year Old Babies
Jayashri Kulkarni1*, Roisin Worsley1, Heather Gilbert1, Emorfia Gavrilidis1, Tamsyn E. Van Rheenen1,
Wei Wang1, Kay McCauley2, Paul Fitzgerald1
1Monash Alfred Psychiatry research centre, Monash University & Alfred Hospital, Melbourne, Victoria, Australia, 2 School of Nursing and Midwifery, Monash University,
Clayton, Victoria Australia
Abstract
Background: Many women diagnosed with varying psychiatric disorders take antipsychotic medications during pregnancy.
The safety of antipsychotic medications in pregnancy is largely unknown.
Methods: We established the National Register of Antipsychotic Medications in Pregnancy in 2005. Women who are
pregnant and taking an antipsychotic medication are interviewed every 6 weeks during pregnancy and then followed until
their babies are one year old. The baby’s progress is closely followed for the first year of life.
Findings: As of April 18 2012, 147 pregnancies had been followed through to completion. There were 142 live births and
data is available for 100 one year old babies. 18% of babies were born preterm, with a higher dose of antipsychotic
medication correlating to an increased likelihood of premature delivery; 43% of babies required special care nursery or
intensive care after birth; 37% had any degree of respiratory distress and 15% of babies developed withdrawal symptoms.
Congenital anomalies were seen in eight babies. Most pregnancies resulted in the birth of live, healthy babies. The use of
mood stabilisers or higher doses of antipsychotics during pregnancy increased the likelihood of babies experiencing
respiratory distress or admission to Special Care Nursery or Neonatal Intensive Care Units.
Conclusion: There is a great need for safety and efficacy information about the use of antipsychotic medications in
pregnancy. Live, healthy babies are the most common outcome following the use of antipsychotic medication in
pregnancy, but clinicians should be particularly mindful of neonatal problems such as respiratory distress.
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Introduction
Mental and behavioural disorders are the largest cause of years
lived with a disability world- wide [1]. Women experience higher
rates of many psychiatric disorders than men and in general
receive more psychotropic medications [1–3]. Many of these
disorders begin in adolescence and young adulthood, affecting
women during their reproductive life. Most women with severe
mental illness will become mothers [4–7] and many mothers will
experience mental illness [8,9]. Yet the care of pregnant and
breastfeeding mothers with mental illness remains poorly re-
searched and under resourced, sometimes with tragic consequenc-
es [10]. Many women with psychiatric illness require psychotropic
medication treatment during pregnancy and postpartum because
there is a 50% or more risk of relapse of bipolar and psychotic
disorders during pregnancy and the immediate postpartum period
[11,12]. The appropriate use of psychotropic medication during
pregnancy substantially reduces the risk of relapse in women with
bipolar disorder [11,13]. Untreated psychosis during pregnancy
and postpartum may lead to disastrous outcomes for the woman,
as well as poor maternal-infant bonding with resultant lifelong
functional impairment for the developing child [14–16].
Antipsychotic medication is increasingly used by women of all
ages [2,17] for schizophrenia, bipolar disorder and a number of
off-label indications such as depression, anxiety and borderline
personality disorder [17,18]. Multiple reviews have highlighted the
lack of evidence regarding antipsychotic use in pregnancy and
breastfeeding [19–24]. Whether antipsychotics exacerbate or
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mitigate the increased rate of stillbirth, prematurity, and obstetric
complications seen in mothers with severe mental illness is
unknown [25–27].
There are two major classes of antipsychotic medications – the
first generation (typical) antipsychotics and the second generation
(atypical) antipsychotics. Typical antipsychotics such as haloper-
idol have a very high affinity for dopamine D2 receptors, which
results in an antipsychotic effect and a high rate of extrapyramidal
side effects (EPS). Atypical antipsychotics such as quetiapine,
olanzapine and risperidone have a lesser affinity for the D2
receptor, with fewer EPS side effects. Antipsychotics also impact
on serotonin, histamine, acetylcholine and NMDA receptors [28–
32]. Antipsychotics readily cross the placental barrier [33] with
placental passage 23.8% for quetiapine and 72.1% for olanzapine
[19,34]. The effects of antipsychotic medication on the fetus,
particularly the fetal brain, are largely unknown but concerning
given adverse findings associated with perinatal exposure to other
psychotropic medications [35–37].
Ensuring quality maternal care and a good start to early life are
recognised priorities in the developed and developing world
[38,39]. Improving the care of mothers with mental illness is
important to achieving such goals.
Methods
The Australian National Register of Antipsychotic Medication
in Pregnancy (NRAMP) was established in 2005 as an ongoing
prospective observational cohort study (Clinical trials number
NCT00686946). The workings of the register have been described
in detail previously [15]. Ethics approval has been obtained from
17 ethics committees Australia-wide (for example, Alfred Hospital
Ethics approval number 114/04).
The Register is based at the Monash Alfred Psychiatry research
centre at the Alfred Hospital in Melbourne, Australia. Women
who take antipsychotic medication during pregnancy and are able
to give informed consent are prospectively recruited during
pregnancy or in the first 12 months after birth. Ongoing treatment
is managed by the woman’s usual treating team. After providing
informed consent women participate in a series of interviews,
conducted in person or by telephone by a trained research nurse.
With consent, information is also sought from treating clinicians
and medical records.
The initial baseline interview involves a comprehensive social,
family, medical, psychiatric, medication and obstetric history. The
Positive and Negative Syndrome Scale (PANSS), a validated
measure of psychopathology, is also administered. Women are
contacted every 6–8 weeks during pregnancy and specifically
asked about weight, oral glucose tolerance test results, nuchal
translucency scan and blood test results, and any particular
problems occurring during pregnancy.
At six weeks post partum the PANSS is repeated and the
Edinburgh Postnatal Depression Scale (EPDS) is also performed
[40]. Details of birthing, breastfeeding, respiratory distress and
neonatal withdrawal symptoms are sought. These symptoms,
which make up the Neonatal Abstinence Syndrome, include, but
are not restricted to, excessive high pitched crying, pronounced
moro reflex, myoclonic jerks, intermittent bouts of sneezing and/
or yawning, excessive drowsiness, tremors, pronounced irritability,
difficulty feeding, vomiting and loose stools [41,42]. Babies who
experience two or more of these symptoms are recorded as having
experienced medication withdrawal.
At 12 weeks, 6 months and 12 months post partum the mothers
are asked about their own health and the babies milestones and
behaviours [43]. Developmental milestones are not covered
further in this article.
For this publication descriptive statistics were performed using
SPSS version 20; t-tests and chi-square tests were used where
appropriate. In addition, logistic regression (via Mplus 7.1) was
used to examine the effects of mothers’ smoking behaviour during
pregnancy (0 = none to 4=.20 cigarettes/day), total dose of
primary and secondary antipsychotic medication in risperidone
equivalents at 12 weeks antenatal, mental health DSM-IV
diagnosis (psychosis vs others), antidepressant, antipsychotics(que-
tiaptine vs others), and mood stabiliser at 12 weeks antenatal on
baby respiratory distress at delivery (no vs yes), admission to
neonatal intensive care/special care nursery (no vs yes), gestation
delivery week (less than 37 weeks vs over 37 weeks), and birth
weight in the cohort with 1 year old babies
Results
Data collected from 2005 up to 18 April 2012 are presented
below. Over this time 192 women were recruited into the study.
Of these, 49 women have been excluded from the analysis. Of the
49, 18 women were lost to follow up and the outcome of their
pregnancy was unknown; 11 women were excluded as although
they were mentally ill they did not require antipsychotic
medication at any time during pregnancy; 20 women were
excluded as they were currently pregnant and we have analysed
data for completed pregnancies only. In total 147 pregnancies
have been followed through to completion. Baseline characteristics
of the women are shown in Table 1. These women were, for the
most part, well-educated and in long-term relationships. Psychotic
disorders and bipolar disorder were equally represented. Many of
the women in this study had moderate to severe psychiatric
disease, with most having had psychiatric hospitalisations at some
time in their life. A small number of pregnancies were achieved
through assisted reproductive techniques (7%), although this is
approximately double the rate for the Australian general
population [44]. Health related behaviours shown are poor, with
smoking during pregnancy 35%, and attendance at antenatal
clinics only 84%.
Table 2 contains data relating to the psychiatric health of the
women during pregnancy. The baseline mean PANSS score was
40, which is consistent with mild psychosis. The most commonly
prescribed antipsychotic agent was quetiapine followed by
olanzapine. Only 11 women used typical antipsychotics. Antipsy-
chotic doses were converted to risperidone equivalents, with the
median dose at 12 weeks gestation being 3 mg/day, compared
with 3.3 mg/day pre pregnancy. The rate of polypharmacy was
high, with 43% of women also taking an antidepressant. The
EPDS was performed at 6 weeks postpartum in 105 women.
Thirty nine percent of the women tested had EPDS scores greater
than 10, indicating possible depression [45].
Pregnancy outcomes are shown in Table 3. Overall, there were
142 live births from 147 pregnancies (including one set of twins).
The rate of instrumental vaginal delivery or caesarean section was
higher compared with the expected rate in Australia [44]. The
reported rate of gestational diabetes was very high at 22%.
Of the 142 live births, 25 were born prematurely (less than 37
weeks gestation). There was a significant difference in total
antipsychotic dose at 12 weeks between babies born at term and
babies born prematurely (2.6 mg vs 5.0 mg p=0.02). Using
Spearman’s Correlation the inverse relationship between total
antipsychotic dose at 12 weeks of pregnancy and gestational age at
birth remained significant, though the effect size was small
(r2 = 0.12, p = 0.01).
Antipsychotics in Pregnancy
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Table 4 presents further data relating to the babies at birth. The
mean birth weight was close to that expected, but there were a
high proportion of babies with low or high birth weights.
Strikingly, the occurrence of respiratory distress (ranging from a
requirement for oral or nasal suctioning to full respiratory
resuscitation) was 37%. Over 40% of babies required care in a
Special Care Nursery (SCN) or Neonatal Intensive Care Unit
(NICU), almost three times the usual rate in the Australian general
population [44]. Low APGAR scores at 5 minutes following birth
were also more common (APGAR scores being a global
standardised measure of infant health at 1 minute and 5 minutes
following birth [46]).
At birth 15% of babies displayed medication withdrawal
symptoms. Babies who experienced withdrawal had been exposed
to higher doses of antipsychotics at 12 weeks gestation (4.4 mg/
day vs 2.7 mg/day) though this did not reach statistical
significance (p = 0.162). Symptoms were prolonged in several
babies, lasting 6–8 weeks.
Congenital anomalies were seen in eight babies. The anomalies
reported were atrial septal defect (ASD), (in a baby with perinatal
exposure to quetiapine and zuclopenthixol); cleft lip/palate and
hydrocephalus in a baby (perinatal quetiapine exposure); pulmo-
nary atresia and ASD (perinatal quetiapine exposure); abnormal
renal collecting tubule and bilateral talipes in a baby (perinatal
risperidone exposure), craniosynostosis, hypospadias and hyper-
telorism in a baby (perinatal clozapine exposure), gastroschisis and
horseshoe kidney in a baby (perinatal clozapine exposure);
bilateral hip dysplasia in a baby (perinatal olanzapine exposure)
and CHARGE syndrome (Coloboma, Heart defects, Choanal
Atresia, Retarded growth, Genital anomalies, Ear anomalies) in a
baby (perinatal risperidone exposure).
At one year post-partum 96 of the babies were regarded by their
mother as ‘progressing well’, whilst four babies were undergoing
further assessment or treatment. Most of the mothers were also
considered to be well at 12 months following the birth, being able
to carry out their normal daily mothering activities, though most
remained out of the paid work force.
Findings suggest that there was no statistical differences between
psychosis (n=39) and bipolar (n=44) groups in relation to birth
weight, birth weeks, respiratory distress at delivery, special care
admission, and mothers’ antenatal and postnatal PANSS (includ-
ing positive, negative, general, and total) scores.
Results of the logistic regression suggest that the babies of
mothers who used mood stabilisers were over six times (OR=6.25)
more likely to experience respiratory distress at delivery than
babies whose mother did not use mood stabilisers during
pregnancy. Moreover, higher total doses of primary and secondary
antipsychotic medication in risperidone equivalents at 12 weeks
antenatal increased the odds of babies being admitted to neonatal
intensive care/special care nursery by 13.4% (OR=1.13).
No effect was found for mothers’ smoking behaviour during
pregnancy, mental health DSM-IV diagnosis, antidepressant use
12 weeks antenatal and antipsychotic medication up to 12 weeks
antenatal on baby respiratory distress at delivery, admission to
neonatal intensive care/special care nursery, gestation delivery
week, and birth weight.
Discussion
NRAMP is the first large scale, prospective, observational study
of women who take antipsychotic medication during pregnancy.
While the eventual aim of the study is to identify the safest
antipsychotic for use in pregnancy, these early data provide many
new and valuable insights into the health and wellbeing of mothers
with severe psychiatric illness and their babies. The increased rates
of adverse events we describe are likely to be the result of a
combination of many factors including medications, the genetic
loading associated with psychiatric illness, particularly schizophre-
nia, increased use of alcohol, tobacco and illicit drugs, and lesser
contact with antenatal care services. Despite this, by 12 months
postpartum we observed good results for most mothers and babies
but there are several issues that clinicians need to be cognisant of
to optimize outcomes.
Prematurity
Premature delivery has been noted in women with schizophre-
nia in multiple studies, though the relationship between total
antipsychotic dose at 12 weeks and gestational age at delivery has
not been noted previously. Whether this is a medication effect or a
sign of more severe underlying illness or another comorbid factor
is not clear.
Neonatal Complications
The most unexpected finding in the babies was the very high
rate of respiratory distress and admission to Special Care Nursery
or Neonatal Intensive Care Units. Importantly, this may have
partially resulted from the impact of mood stabiliser or antipsy-
chotic medication use during pregnancy, as the babies of women
who were taking mood stabilisers were over six times more likely
than the babies of women who weren’t taking mood stabilisers to
experience respiratory distress at delivery. Higher doses of
antipsychotic use also increased the likelihood of babies being
Table 1. Characteristics of mothers in pregnancy.
Baseline Characteristic
Number of women
(%)
Age, years (mean 6 SD) 32.67 (64?7)
Weight, kg (mean 6 SD) 75.58 (618?77)
BMI (mean 6 SD) 27.14 (66?45)
Married/de facto (n = 141) 109 (77%)
University degree (n = 140) 85 (61%)
Employed/studying during pregnancy(n = 140) 71 (50%)
Conception from assisted reproductive technology
(n = 144)
10 (7%)
Diagnosis (n = 146)
Psychotic disorders 62 (42.5%)
Bipolar Disorder 61 (42%)
Depression 14 (10%)
Severe anxiety disorder 5 (3.5%)
Obsessive Compulsive Disorder 2 (1%)
Borderline Personality Disorder 2 (1%)
Psychiatric admissions prior to pregnancy (n = 134)
At least one 108 (81%)
More than five 35 (26%)
Smoking during pregnancy (n = 140) 50 (35%)
Alcohol use during pregnancy (n = 138) 36 (26%)
Illicit drug use during pregnancy (n = 140) 17 (12%)
Antenatal clinic attendance (n = 63) 53 (84%)
Gestational Diabetes (n = 138) 30 (22%)
doi:10.1371/journal.pone.0094788.t001
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admitted to Special Care Nursery or Neonatal Intensive Care
Units.
These findings certainly highlight the potentially damaging
effects of these medications on neonatal outcomes and suggest that
careful consideration needs to be taken by doctors prescribing
these medications during pregnancy. Interestingly, despite a
heightened rate of smoking during pregnancy in women in
NRAMP (35% compared to the national Australian average of
13.5% [47]), smoking did not predict neonatal complications; this
is likely to reflect the relatively small numbers of women in the
study. The high use of concurrent antidepressants also did not
influence outcomes, despite the fact that approximately 43% of
participants in NRAMP took both antipsychotics and antidepres-
sants during pregnancy, compared to the US national antidepres-
sant use average of 8% [48,49]. Medication withdrawal symptoms
however, might also play a significant role in neonatal complica-
tions. As we have previously reported, babies breast fed at birth
experienced medication withdrawal symptoms at less than half the
rate of babies who were bottle fed [50]. It has been demonstrated
that haloperidol is transferred into breast milk and found in
detectable quantities in breastfed infants’ urine and serum [51].
Our findings suggest that other antipsychotic medications are also
transmitted via breast milk at concentrations high enough to have
an effect on the infant brain. The significance of this in both the
short and longer term is unknown and requires further research.
Table 2. Maternal psychiatric progress and psychotropic medications.
Total dose of antipsychotic medication in risperidone equivalents prior to pregnancy, mg (n = 142) (mean 6 SD) 3?3 (±3?5)
Total dose of antipsychotic medication in ripseridone equivalents at 12 weeks, mg (n = 143) (mean 6 SD) 3?0 (±3?3)
Antipsychotic used in the first trimester (n = 147)
Quetiapine 74 (50%)
Olanzapine 24 (16%)
Aripiprazole 19 (13%)
Risperidone 15 (10%)
Clozapine 11 (7?5%)
Haloperidol 6 (4%)
Amisulpride, Ziprasidone, Zuclopenthixol 2 each (1?5%)
Trifluoperazine 1 (0?5%)
None 5 (3?5%)
Use of two antipsychotics (n = 144) 16 (11%)
Concurrent use of at least one antidepressant during pregnancy(n = 143) 62 (43%)
Use of a second antidepressant during pregnancy (n = 142) 6 (4%)
Concurrent use of a mood stabiliser during pregnancy (n = 142) 10 (7%)
PANSS score during pregnancy (n = 86) (mean 6 SD) 40 (610)
PANSS score 6 weeks post partum (n = 99) (mean 6 SD) 40?5 (611)
EPDS score at 6 weeks post partum (n = 105) (mean 6 SD) 8?4 (67?5)
EPDS$10 41 (39%)
Antenatal psychiatric admission (n = 139) 25 (18%)
Postnatal psychiatric admission (n = 125) 37 (30%)
doi:10.1371/journal.pone.0094788.t002
Table 3. Pregnancy outcomes and mode of delivery.
Number (percent) Expected rate in Australia [44]
Pregnancy outcome (n = 147 pregnancies resulting in 148 babies) 7?5 per 1000 births
Live birth 142 (95?9%)
Miscarriage ,20 weeks 4 (2?7%)
Stillbirth $20 weeks 1 (0?7%)
Ectopic pregnancy 1 (0?7%)
Delivery mode (n = 138)
Normal vaginal delivery 66 (48%) 56?8%
Instrumental vaginal delivery 17 (12%) 11?7%
Caesarean section 55 (40%) 31?5%
doi:10.1371/journal.pone.0094788.t003
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Congenital Abnormalities
Akin to other studies, we found a higher rate of congenital
malformations compared with the expected rate in Australia,
particularly congenital heart anomalies [52]. Of 11 babies in our
cohort with perinatal clozapine exposure, two babies were born
with major congenital anomalies.
Birthweight
Earlier studies have reported higher birth weights in those
exposed to atypical compared to typical antipsychotics, a
relationship not examined in NRAMP due to an overwhelming
preference for atypical antipsychotics [53]. The dose of antipsy-
chotic medication in risperidone equivalents showed only a small
correlation with birth weight (Spearman’s rho r2 0.04 p= 0.02).
We found that the incidence of both large and small for gestational
age birth weight was high, comparable to a previous case-control
study [54].
Maternal Metabolic Effects
NRAMP mothers experienced high rates of weight gain and
gestational diabetes (GDM) during pregnancy. Increased likeli-
hood of GDM with antipsychotic use has been reported in several
other studies (OR 1.77–1.94) but to a lesser extent than in
NRAMP [52,55].
Maternal Psychiatric Morbidity
Despite receiving medication many women were hospitalised
during, or within the first year after pregnancy. The increased
volume of distribution and drug clearance during pregnancy
results in an increased dose being required to achieve the same
serum concentrations of drug [56]. The high prevalence of EPDS
scores greater than ten, supports the known high rates of postnatal
depression in women with mental illness [57], with its many
implications for the mother, maternal-infant bonding and child
development [58].
The main limitation of this analysis is the lack of a control group
to tease out the effects of medication as compared to illness. The
next phase of NRAMP will address this issue. These early findings
however, are still of relevance as they give clinicians a guide as to
the difficulties they may encounter when treating pregnant women
with mental illness that requires antipsychotic medication. There is
clearly a need for further research and with ongoing and
increasing recruitment we hope to determine the safest antipsy-
chotics to use during pregnancy. It is vital to pursue this research
aggressively and extend the longitudinal follow-up.
Conclusion
In a small but growing number of women, antipsychotic
medication is necessary for the mental health and well-being of the
mother to be, and consequently, her baby. There is a lack of an
evidence-base for clinicians and women to make informed
decisions that balance the needs of the mother and baby. The
NRAMP study should alert clinicians to the high risks confronting
this vulnerable group. In particular, mothers face high rates of
psychiatric admission and gestational diabetes, while babies
frequently experience respiratory distress and medication with-
drawal symptoms. Although higher antipsychotic doses and mood
stabilisers may increase the risk of neonatal adverse events,
clinicians and women should be reassured that positive longer-
term outcomes occur in the vast majority of pregnancies. This
information should be used constructively to optimise the health of
mothers with mental illness and their babies.
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